{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-042843","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2026-09-16T12:30:43+00:00","discovered_at":"2026-09-16T12:35:01.918419+00:00","generated_at":"2026-09-16T12:35:14.539150+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Oragenics CMO to present ONP-002 at IPAC-RS; IND submission planned Q4 2026","bullets":["CMO James P. Kelly presents ONP-002 intranasal neurosteroid for concussion at IPAC-RS 2026 Nasal Innovation Forum on Sept 17, 2026.","Phase IIa feasibility trial enrolling at 3 Australian sites; IND submission anticipated Q4 2026.","U.S. Phase IIb trials planned post-IND; no FDA-approved pharmacological treatment for mTBI exists.","Phase I safety trials completed with favorable safety/tolerability; ONP-002 targets neuroinflammation, oxidative stress, edema."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-042843","json":"https://secwatch.observer/filing/0001493152-26-042843.json","markdown":"https://secwatch.observer/filing/0001493152-26-042843.md","text":"https://secwatch.observer/filing/0001493152-26-042843.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226042843/0001493152-26-042843-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315226042843/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T12:35:14.539150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}